Belgian eye biotech gets hammered by investors after PhII trial fails efficacy on key endpoints

Paul Schloesser

Associate Editor

Belgian biotech and penny stock player Oxurion was already hovering around the $1.06/share mark this past week on the Euronext stock exchange in Brussels …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Belgian eye biotech gets hammered by investors after PhII trial fails efficacy on key endpoints

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Biotech VC firm outlines plans for $100M fund

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Breaking down silos with a new quantitative approach to drug development

Bel­gian eye biotech gets ham­mered by in­vestors af­ter PhII tri­al fails ef­fi­ca­cy on key end­points

Associate Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Belgian eye biotech gets hammered by investors after PhII trial fails efficacy on key endpoints